Optimum cancer care - An unaffordable goal?

Lancet Oncology

Volumn 5, Issue 9, 2004, Pages 529-530

  Ludwig, Heinz ^a   Thorat, Mangesh ^b  

^a WILHELMINEN HOSPITAL   (Austria)

^b TATA MEMORIAL HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN;

BLOOD TOXICITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COST BENEFIT ANALYSIS; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; HEAD AND NECK CANCER; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH CARE QUALITY; HUMAN; MEDICAL DECISION MAKING; METASTASIS; NOTE; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; STANDARDIZATION; SURVIVAL TIME; TREATMENT PLANNING; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; HEAD AND NECK TUMOR;

CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; HEAD AND NECK NEOPLASMS; HUMANS; RADIOTHERAPY, ADJUVANT;

EID: 4444383037     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(04)01563-3     Document Type: Letter

References (6)

1. Hurwitz H. Fehrenbacher L. Novotny W. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335-2342
2. Cunningham D. Humblet Y. Siena S. et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2003; 22: 252 (abstr).
3. Stewart B.W. Kleihues P. eds. WHO World Cancer Report. Lyon: IARC Press, 2003.
4. Centers for Medicare and Medicaid Services. National health care expenditures: projections table based on the intermediate set of economic and demographic assumptions from the 2002 annual reports of the Medicare Board of Trustees. http://www.cms.hhs.gov/statistics/nhe/projections-2002/t2.asp (accessed August, 2004).
5. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1937-44.
6. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945-52.